GlassScriptPhysician profile
Patrick M Vannelli
NPI 1316079676
$7,358.74
in general payments reported to CMS, 2019-2025
28 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $308 · 2021: $714 · 2022: $861 · 2023: $925 · 2024: $1,860 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,704.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,940.33 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,424.84 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $767.85 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $496.93 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Kaleo, INC. | $460.34 | 2019-2024 | Auvi-Q |
| Csl Behring | $343.72 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Alk-Abello, INC | $297.73 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $289.91 | 2019-2025 | Dupixent |
| Amgen INC. | $264.97 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $148.07 | 2019-2025 | |
| Grifols USA, LLC | $143.38 | 2023-2025 | Xembify |
| Genentech USA, INC. | $128.19 | 2021-2025 | Xolair |
| Blueprint Medicines Corporation | $102.32 | 2024-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $82.18 | 2025 | Neffy |
| Covis Pharma Gmbh | $77.32 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $71.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.30 | 2019-2023 | |
| Optinose US, INC. | $46.79 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $31.57 | 2025 | Orladeyo |
| Verona Pharma, INC. | $26.49 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $25.50 | 2025 | Dawnzera |
| Paratek Pharmaceuticals, INC. | $22.39 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $19.97 | 2023 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $19.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.34 | 2021 | |
| Cycle Pharmaceuticals INC | $17.94 | 2025 | Sajazir |
| Philips North America LLC | $16.89 | 2019 | |
| Shire North American Group INC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Vannelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.